Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 26.10.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. IN2371/MUMNP/2009 - INACTIVATED STAPHYLOCOCCAL WHOLE-CELL VACCINE

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]
1. A vaccine composition comprising an inactivated staphylococcal cellwherein said composition is prepared using a staphylococcal cell characterised inthat said cell:i) is a gram positive cocci;ii) expresses at least the enzyme catalase;iii) induces an immune response that produces antibodies that bind at least staphylococcal collagen-binding protein; andiv) is resistant to the antibiotic penicillin. 2. The vaccine composition according to claim 1 wherein said staphylococcal cell also expresses the enzymes coagulase and/or Dnase. 3. The vaccine composition according to claim 1 or 2 wherein said staphylococcal cell induces an immune response that produces antibodies that bind collagen binding protein 4. The vaccine composition according to any of claims 1-3 wherein said inactivated staphylococcal cell induces an immune response that produces antibodies that cross react with methicillin resistant, vancomycin resistant and vancomycin intermediate resistant staphylococcal species. 5. The vaccine composition according to any of claims 1-4 wherein said staphylococcal cell is sensitive to the antibiotics cloxacillin, erythromycin, tetracycline or gentamicin 6. The vaccine according to any of claims 1-5 wherein said staphylococcal cell is selected from the group consisting of: S.epidermidis, S.aureus, S.hominis, S. haemolyticus, S. warneri, S. capitis, S.saccharolyticus, S. auricularis, S.simulans, S.saprophyticus, S.cohnii, S.xylosus, S.cohnii, S.warneri, S.hyicus, S.caprae, S.gallinarum, S.intermedius, S.hominis. 7. The vaccine composition according to claim 6 wherein said staphylococcal cell is S. aureus or S. epidermidis. 8. The vaccine composition according to claim 6 or 7 wherein said S. aureus or S. epidermidis is antibiotic resistant. 9. The vaccine composition according to claim 8 wherein said antibiotic resistance is a methicillin resistant staphylococcal cell (MRSA). 10. The vaccine composition according to claim 8 wherein said antibiotic resistance staphylococcal species is a vancomycin resistant staphylococcal cell (VRSA). 11. The vaccine composition according to any of claims 1-7 wherein said staphylococcal cell is Staphylococcus aureus (accession number 13408). 12. The vaccine composition according to any of claims 1-11 wherein said staphylococcal cell is provided at a protein concentration of not more than about 1 .Omg or 0.45mg bacterial protein/ml. 13. The vaccine composition according to any of claims 1-11 wherein said staphylococcal cell is provided at a protein concentration of at least 0.000 Img or 0.1 mg bacterial protein/ml 14. The vaccine composition according to any of claims 1-11 wherein said staphylococcal cell is provided at a protein concentration of between 0.0001-lmg bacterial protein/ml. 15. The vaccine composition according to any of claims 1-11 wherein said staphylococcal cell is provided at a protein concentration of between 0.1-0.45mg bacterial protein/ml. 16. The vaccine composition according to any of claims 1-11 wherein said . staphylococcal cell is provided at between 0.25-0.36mg bacterial protein/ml. 17. The vaccine composition according to any of claims 1-11 wherein said staphylococcal cell is provided at about 0.35mg bacterial protein/ml. 18. The vaccine composition according to any of claims 1-17 wherein said vaccine comprises an adjuvant and/or excipient. 19. The vaccine composition according to any of claims 1-18 wherein said composition includes at least one additional anti-bacterial agent to provide a combination therapy. 20. The vaccine composition according to claim 19 wherein said agent is a second different vaccine and/or immunogenic agent. 21. The vaccine composition according to any of claims 1-20 wherein said vaccine composition is adapted for administration as a nasal spray. 22. The vaccine composition according to claim 21 wherein said composition is provided in an inhaler and delivered as an aerosol. 23. An inhaler comprising a vaccine composition according to any of claims 1-22. 24. A staphylococcal cell wherein said cell comprises the followingcharacterising features:i) is a gram positive cocci;ii) expresses at least the enzyme catalase;iii) induces an immune response that produces antibodies that bind at least staphylococcal collagen-binding protein; andiv) is resistant to the antibiotic penicillin,for use in the preparation of a vaccine. 25. A staphylococcal cell wherein said cell comprises the followingcharacterising features:i) is a gram positive cocci;ii) expresses at least the enzyme catalase;iii) induces an immune response that produces antibodies that bind at least staphylococcal collagen-binding protein;iv) is resistant to the antibiotic penicillin;for use in the manufacture of a vaccine composition for the vaccination of an animal subject with respect to a bacterial infection wherein said infection is not caused by a staphylococcal bacterial species. 26. A vaccine composition according to claim 25 wherein said bacterialinfection is caused by at least one bacterial species selected from the groupconsisting of: Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcusgroup B; Streptoccocus pneumoniae; Helicobacter pylori; Neisseriagonorrhoea; Streptococcus group A; Borrelia burgdorferi; Coccidiodes immitis;Histoplasma sapsulatum; Klebsiella edwardii; Neisseria meningitidis type B;Proteus mirabilis; Shigella flexneri; Escherichia coli; Haemophilus influenzae,Chalmydia trachomatis, Chlamydia pneumoniae, Chlamydia psittaci,Francisella tularensis, Pseudomonas aeruginos, Bacillus anthracis, Clostridiumbotulinum, Yersinia pestis, Burkholderia mallei or B pseudomallei. 27. A vaccine composition according to claim 25 or 26 wherein said animal subject is human. 28. A method for preparing a hybridoma cell-line producing monoclonal antibodies that bind staphylococcal bacterial polypeptides comprising the steps of:i) vaccinating an immunocompetent mammal with a vaccinecomposition according to any of claims 1-20; ii) fusing lymphocytes of the vaccinated immunocompetent mammalwith myeloma cells to form hybridoma cells; iii) screening monoclonal antibodies produced by the hybridoma cells ofstep (ii) for binding activity with respect to staphylococcal bacterialpolypeptides; v) cloning the hybridoma cells and culturing the cells to proliferate andto secrete said monoclonal antibody; and vi) recovering the monoclonal antibody from the culture supernatant. 29. A method according to claim 28 wherein said immunocompetent mammal is a mouse. 30. A method according to claim 28 wherein said immunocompetent mammal is a rat. 31. A hybridoma cell line formed by the method according to any of claims 28-30. 32. A monoclonal antibody produced by the hybridoma cell-line according to claim 31. 33. A monoclonal antibody according to claim 32 wherein said monoclonal antibody is an opsonic antibody. 34. A monoclonal antibody according to claim 32 or 33 wherein said monoclonal antibody is a chimeric or humanized antibody. 35. An active binding fragment of the monoclonal antibody according to claim32 or 33. 36. A human antibody obtained by vaccination of a human subject with a vaccine composition according to any of claims 1-20. 37. The human antibody according to claim 36 wherein said antibody is an isotype selected from the group consisting of: IgA, IgM, IgD, IgE and IgG. 38. A method to prepare a vaccine to a bacterial pathogen comprising the stepsof:i) forming a cell culture preparation comprising at least one bacterial pathogen and nutrient broth comprising plant derived products;ii) culturing said cell culture preparation; andiii) contacting said cell culture preparation with an agent that inactivates said bacterial pathogen. 39. A method according to claim 38 wherein said bacterial pathogen is selected from the group consisting of: Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcus group B; Streptoccocus pneumoniae; Helicobacter pylori; Neisseria gonorrhoea; Streptococcus group A; Borrelia burgdorferi; Coccidiodes immitis; Histoplasma sapsulatum; Klebsiella edwardii; Neisseria meningitidis type B; Proteus mirabilis; Shigella flexneri; Escherichia coli; Haemophilus influenzae, Chalmydia trachomatis, Chlamydia pneumoniae, Chlamydia psittaci, Francisella tularensis, Pseudomonas aeruginos, Bacillus anthracis, Clostridium botulinum, Yersinia pestis, Burkholderia mallei or B pseudomallei. 40. A method according to claim 38 wherein said bacterial pathogen is selected from the group consisting of: S.epidermidis, S.aureus, S.hominis, S.haemolyticus, S.warneri, S.capitis, S.saccharolyticus, S.auricularis, S.simulans, S.saprophyticus, S.cohnii, S.xylosus, S.cohnii, S.warneri, S.hyicus, S.caprae, S.gallinarum, S.intermedius, S.hominis. 41. A method according to claim 40 wherein said bacterial pathogen isStaphylococcus aureus or Staphylococcus epidermidis. 42. A method according to claim 38 wherein said bacterial pathogen is selected from the group consisting of: Streptococcus pneumoniae, Pseudomonas aeruginosa or Eschericia coli. 43. A method according to any of claims 38-42 wherein said plant derived product is vegetable peptone. 44. A method according to claim 43 wherein said vegetable peptone includes pea flour and/or tryptone soya. 45. A method according to any of claims 38-44 wherein said bacterial pathogen is inactivated with chloroform. 46. A method according to any of claims 38-45 wherein said bacterial pathogen is isolated from said cell culture preparation and freeze dried. 47. A process for the production of a vaccine comprising the steps of:i) forming a preparation comprising a staphylococcal bacterial cells;ii) contacting the preparation with an agent that inactivates the staphylococcal bacterial cells;iii) isolating the inactivated staphylococcal bacterial cells;iv) shearing said preparation to disaggregate the inactivated bacteria; and optionallyv) freeze drying said inactivated staphylococcal bacterial cells 48. A process according to claim 47 wherein said staphylococcal cell is selectedfrom the group consisting of: S.epidermidis, S.aureus, S.hominis,S. haemolyticus, S. warneri, S. capitis, S. saccharolyticus, S. auricularis,S.simulans, S.saprophyticus, S.cohnii, S.xylosus, S.cohnii, S.warneri, S.hyicus,S.caprae, S.gallinarum, S.intermedius, S.hominis. 49. A process according to claim 48 wherein said staphylococcal bacterial cells are Staphylococcus aureus or Staphylococcus epidermidis. 50. A process according to any of claims 47-49 wherein said agent is chloroform. 51. A process according to any of claims 47-50 wherein shear force is provided by a dounce homogenizer. 52. A Staphylococcus aureus cell as deposited under accession 13408. 53. A bacterial cell culture comprising a Staphylococcus aureus cell as deposited under accession number 13408.